![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ADU-1805 is a monoclonal antibody which blocks SIRPα, a significant immune-suppressive component of the tumor microenvironment which leads in improved immune system’s ability to attack tumors.
Lead Product(s): ADU-1805
Therapeutic Area: Oncology Product Name: ADU-1805
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Exelixis
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2023
Details:
Exelixis and Sairopa will develop ADU-1805, a potentially best-in-class monoclonal antibody that targets SIRPα. ADU-1805 is active against all human alleles of SIRPα, which may allow it to address a broader patient population than other SIRPα-directed therapies.
Lead Product(s): ADU-1805
Therapeutic Area: Oncology Product Name: ADU-1805
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Exelixis
Deal Size: $335.0 million Upfront Cash: $40.0 million
Deal Type: Collaboration November 01, 2022